Spots Global Cancer Trial Database for almonertinib

Every month we try and update this database with for almonertinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection	NCT04762459	Non-small Cell ...	Almonertinib Pemetrexed Cisplatin	18 Years - 130 Years	ChineseAMS
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC	NCT04636593	Non Small Cell ... Stage III NSCLC EGFR Activating...	Almonertinib	18 Years -	First People's Hospital of Hangzhou
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status	NCT05826483	Malignant Tumor... Poor Performanc...	Almonertinib	18 Years -	Guangzhou Institute of Respiratory Disease
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases	NCT04870190	NSCLC	Almonertinib Osimertinib	18 Years -	Shanghai Chest Hospital
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment	NCT04882345	Lung Cancer EGFR Gene Mutat...	Almonertinib	18 Years - 75 Years	Shanghai Chest Hospital
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC	NCT04500704	Non Small Cell ...	Almonertinib Almonertinib pl...	18 Years - 75 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer	NCT05994339	Lung Cancer Sta...	Almonertinib	18 Years - 80 Years	Laibin People's Hospital
Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma	NCT04354961	Pulmonary Adeno...	Almonertinib	18 Years - 75 Years	Fujian Cancer Hospital
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)	NCT04778800	NSCLC Brain Metastase... Leptomeningeal ...	almonertinib LM-first line t... LM-second line ...	18 Years -	Henan Cancer Hospital
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection	NCT04762459	Non-small Cell ...	Almonertinib Pemetrexed Cisplatin	18 Years - 130 Years	ChineseAMS
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC	NCT04500704	Non Small Cell ...	Almonertinib Almonertinib pl...	18 Years - 75 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer	NCT04592666	Lung Cancer, No... EGFR T790M EGFR Gene Mutat...	Almonertinib Pemetrexed Carboplatin	18 Years - 75 Years	Fudan University
Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases	NCT04808752	Lung Cancer	Almonertinib	18 Years - 75 Years	Zhejiang Cancer Hospital
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation	NCT04500717	Non Small Cell ...	Almonertinib Almonertinib pl...	18 Years - 75 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation	NCT04951648	Non-small Cell ...	Almonertinib chemotherapy	18 Years -	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer	NCT05503888	Relapsed or Adv...	Almonertinib co... Almonertinib	18 Years - 75 Years	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases	NCT04643847	EGFR Positive N... Brain Metastase...	Almonertinib	18 Years -	First People's Hospital of Hangzhou
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases	NCT05768490	Brain Metastase... Radiotherapy EGFR Activating...	brain radiother... Almonertinib	18 Years - 75 Years	Sun Yat-sen University
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer	NCT05994339	Lung Cancer Sta...	Almonertinib	18 Years - 80 Years	Laibin People's Hospital
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance	NCT06043973	Advanced Non-sm...	almonertinib	18 Years - 75 Years	Qianfoshan Hospital
MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.	NCT04841811	Lung Cancer	Almonertinib	18 Years - 70 Years	Guangdong Association of Clinical Trials
Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy	NCT05662813	Non-small Cell ...	Almonertinib	18 Years -	West China Hospital
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis	NCT04944069	NSCLC Leptomeningeal ... EGFR Activating...	Almonertinib Bevacizumab	18 Years - 75 Years	Second Affiliated Hospital of Nanchang University
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection	NCT04762459	Non-small Cell ...	Almonertinib Pemetrexed Cisplatin	18 Years - 130 Years	ChineseAMS
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases	NCT05768490	Brain Metastase... Radiotherapy EGFR Activating...	brain radiother... Almonertinib	18 Years - 75 Years	Sun Yat-sen University
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations	NCT04687241	Non-small Cell ...	Almonertinib Placebo Almoner...	18 Years -	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy	NCT05662813	Non-small Cell ...	Almonertinib	18 Years -	West China Hospital
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases	NCT04870190	NSCLC	Almonertinib Osimertinib	18 Years -	Shanghai Chest Hospital
MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.	NCT04841811	Lung Cancer	Almonertinib	18 Years - 70 Years	Guangdong Association of Clinical Trials
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC	NCT04455594	Non-Small Cell ...	Almonertinib Erlotinib Cisplatin Carboplatin Pemetrexed	18 Years - 75 Years	The First Affiliated Hospital of Guangzhou Medical University
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC	NCT04636593	Non Small Cell ... Stage III NSCLC EGFR Activating...	Almonertinib	18 Years -	First People's Hospital of Hangzhou
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC	NCT04952168	NSCLC, Stage II...	Almonertinib	18 Years -	Tongji Hospital

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: